ISNES, Belgium, April 27, 2015 /PRNewswire/ — iSTAR Medical SA, a Belgium ophthalmic device company, announced today the appointment of Michel Lussier as Chairman of the company’s Board of Directors.
Mr. Lussier brings over 30 years of experience in medical technology to iSTAR. He is currently co-founder and Chairman of Cardio3 BioSciences, a publicly traded Belgium company, and serves on several medical technology start-up boards. From 2002 to 2013, Mr. Lussier built and led the European subsidiary as well as the Global Clinical and Scientific Affairs of Volcano Corporation. From 1998 to 2002, as Vice President and General Manager, he founded the European subsidiary of Novoste Corp., a medical technology company. In 2002, he founded Medpole S.A./N.V., a European distribution incubator for medical device start-up companies located in Belgium. Mr. Lussier started his career at Medtronic, where he led the company’s core business in Europe as Business Director, Cardiac Pacing, before founding and leading the European subsidiary of InControl Corp until its acquisition by Guidant. He currently shares his time between Europe and Southern California, where he is a Managing Director of Fjord Ventures, a medical technology accelerator, and the CEO of Metronom Health, Inc. Mr. Lussier received a B.S. in Electrical Engineering and an M.S. in Biomedical Engineering from the University of Montreal, Canada and an M.B.A. from INSEAD, France.
“Michel Lussier brings a unique blend of executive management experience and successful track record in developing start-up organizations. His guidance will be a major asset for iSTAR Medical as the company transitions from its current research and development stage to a global player in the field of glaucoma management,” said Michel Vanbrabant, CEO of iSTAR Medical. “At iSTAR, we remain focused on the advanced development of innovative ophthalmic implants for the treatment of glaucoma and other eye diseases utilizing our proprietary STAR® Biomaterial.”
About Glaucoma and STARfloTM
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it is estimated that 80 million people will have the disease. Elevated intraocular pressure is considered a major risk factor for glaucoma and its progression. STARflo is a non-degradable, precision-pore, implant made from STAR® Biomaterial. It is designed to operate as a bleb-free, micro-porous drainage system to reduce intraocular pressure (IOP) in patients suffering from open-angle glaucoma by augmenting the eye’s natural uveoscleral outflow.